Changes in pneumococcal nasopharyngeal colonization among children with respiratory tract infections before and after use of the two new extended-valency pneumococcal conjugated vaccines

Infectious Diseases

Volumn 47, Issue 6, 2015, Pages 385-392

  Ahn, Jong Gyun ^a,b   Choi, Seong Yeol ^c   Kim, Dong Soo ^b,c   Kim, Ki Hwan ^b,c  

^a Ewha Womans University School of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Nasopharyngeal colonization; Pneumococcal conjugate vaccine; Serotype; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS VACCINE; PHID-CV VACCINE; PREVENAR13;

ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; CHILD; CHILDHOOD DISEASE; FEMALE; HUMAN; INFANT; KOREAN (PEOPLE); MAJOR CLINICAL STUDY; MALE; MUCOSAL IMMUNITY; MULTIPLEX POLYMERASE CHAIN REACTION; NASOPHARYNGEAL ASPIRATION; NASOPHARYNX; RESPIRATORY TRACT INFECTION; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; VACCINATION; CLASSIFICATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; PRESCHOOL CHILD; RESPIRATORY TRACT INFECTIONS; SOUTH KOREA; TIME;

CHILD, PRESCHOOL; FEMALE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; HUMANS; INFANT; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; NASOPHARYNX; PNEUMOCOCCAL VACCINES; REPUBLIC OF KOREA; RESPIRATORY TRACT INFECTIONS; SEROGROUP; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS;

EID: 84945268698     PISSN: 23744235     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365548.2014.1001997     Document Type: Article

References (25)

1. Bogaert D, De Groot R, Hermans PW Streptococcus pneumoniae colonisation: the key to pneumococcal disease Lancet Infect Dis 2004; 4: 144-54.
2. Millar EV, O' B rien KL, W att JP, Bronsdon MA, Dallas J, Whitney CG, et al Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population Clin Infect Dis 2006; 43: 8-15.
3. Huang SS, Hinrichsen VL, Stevenson AE, Rifas-Shiman SL, Kleinman K, Pelton SI, et al Continued impact of pneumococcal conjugate vaccine on carriage in young children Pediatrics 2009; 124: e1-11.
4. Ghaffar F, Barton T, Lozano J, Muniz L S, Hicks P, Gan V, et al Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life Clin Infect Dis 2004; 39: 930-8.
5. Choi EH, Kim KH, Kim YJ, Kim JH, Park SE, Lee HJ, e t al Recommendation for use of the newly introduced pneumococcal protein conjugate vaccines in Korea Korean J Pediatr 2011; 54: 146-51.
6. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine J Infect Dis 2010; 201: 32-41.
7. Ahn J G, Choi S Y, Kim D S, Kim K H.Enhanced detection and serotyping of Streptococcus pneumoniae using multiplex polymerase chain reaction Korean J Pediatr 2012; 55: 424-9.
8. Ben-Shimol S, Greenberg D, Givon-Lavi N, Elias N, Glikman D, Rubinstein U, et al Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel Vaccine 2012; 30: 6600-7.
9. Ben-Shimol S, Greenberg D, Givon-Lavi N, Schlesinger Y, Somekh E, Aviner S, et al Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children-5 years: an active prospective nationwide surveillance Vaccine 2014; 32: 3452-9.
10. Moore M R, Hyde TB, Hennessy TW, Parks D J, Reasonover AL, Harker-Jones M, et al Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska J Infect Dis 2004; 190: 2031-8.
11. Park S Y, Moore M R, Bruden D L, Hyde TB, Reasonover AL, Harker-Jones M, et al Impact of conjugate vaccine on transmission of antimicrobial-resistant Streptococcus pneumoniae among Alaskan children Pediatr Infect Dis J 2008; 27: 335-40.
12. Grivea IN, Panagiotou M, Tsantouli A G, Syrogiannopoulos GA Impact of heptavalent pneumococcal conjugate vaccine on nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae among day-care center attendees in central Greece Pediatr Infect Dis J 2008; 27: 519-25.
13. Prymula R, Hanovcova I, Splino M, Kriz P, Motlova J, Lebedova V, et al Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage Vaccine 2011; 29: 1959-67.
14. Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E.Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media Pediatr Infect Dis J 2012; 31: 297-301.
15. Cho E Y, Kang H M, Lee J, Kang J H, Choi E H, Lee H J.Changes in serotype distribution and antibiotic resistance of nasopharyngeal isolates of Streptococcus pneumoniae from children in Korea, after optional use of the 7-valent conjugate vaccine J Korean Med Sci 2012; 27: 716-22.
16. Vesikari T, W ysocki J, Chevallier B, Karvonen A, Czajka H, Arsene JP, et al Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine Pediatr Infect Dis J 2009; 28: S66-76.
17. Kieninger DM, Kueper K, Steul K, Juergens C, Ahlers N, Baker S, et al Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany Vaccine 2010; 28: 4192-203.
18. Choi E H, Kim S H, Eun B W, Kim S J, Kim N H, Lee J, e t a l Streptococcus pneumoniae serotype 19A in children, South Korea Emerg Infect Dis 2008; 14: 275-81.
19. Reinert R, Jacobs M R, Kaplan S L.Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development Vaccine 2010; 28: 4249-59.
20. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, et al Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004 J Infect Dis 2007; 196: 1346-54.
21. Moore MR, Gertz RE Jr, W oodbury RL, Barkocy-Gallagher GA, Schaffner W, Lexau C, et al Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005 J Infect Dis 2008; 197: 1016-27.
22. Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, Porat N.Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population J Infect Dis 2009; 199: 776-85.
23. Dagan R, Patterson S, Juergens C, Greenberg D, Givon-Lavi N, Porat N, et al Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized doubleblind trial Clin Infect Dis 2013; 57: 952-62.
24. Hausdorff WP, Hoet B, Schuerman L.Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr 2010; 10: 4.
25. Poolman J, Frasch C, Nurkka A, Kayhty H, Biemans R, Schuerman L.Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines Clin Vaccine Immunol 2011; 18: 327-36.